Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement

EuroIntervention 2015;10:1015-1021. DOI: 10.4244/EIJV10I9A174

Davide Capodanno
Davide Capodanno1, MD, PhD; Gregory Y.H. Lip2, MD; Stephan Windecker3, MD; Kurt Huber4, MD; Paulus Kirchhof5, MD; Giuseppe Boriani6, MD; Deirdre Lane7, PhD; Martine Gilard8, MD; Jean-Philippe Collet9, MD, PhD; Marco Valgimigli10, MD, PhD; Robert A. Byrne11*, MB, BCh, PhD
1. Ferrarotto Hospital, University of Catania, Catania, Italy; 2. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; 3. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 4. 3

Oral anticoagulation (OAC) is indicated for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and at least one risk factor for stroke1. However, managing OAC is a challenge in NVAF patients who also require dual antiplatelet therapy (DAPT) in the setting of a presentation with an acute coronary syndrome (ACS) or where percutaneous coronary intervention (PCI) is undertaken2,3. In 2010, the European Society of Cardiology (ESC) Working Group on Thrombosis, in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the European Heart Rhythm Association (EHRA), published an expert consensus document on antithrombotic management of NVAF ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Standards of care: The EAPCI, guidelines and consensus documents

Latest news